CAR T-cell and Cellular Therapies

DRUG2 trials

Sponsors

Groupe Hospitalier Pitie-Salpetriere, Princess Maxima Center for Pediatric Oncology

Conditions

Adverse Drug ReactionsCancerLeukemiaLymphoma

Phase 1

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

Not yet recruitingNCT07020260

Princess Maxima Center for Pediatric OncologyLeukemia, Lymphoma

Start: 2025-09-01End: 2028-09-01Target: 18Updated: 2025-06-13

Unknown Phase

Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events

CompletedNCT04279470

Groupe Hospitalier Pitie-SalpetriereAdverse Drug Reactions, Cancer

Start: 2019-01-01End: 2023-04-08Updated: 2023-04-13